BP
SAGE

Ballentine Partners’s Sage Therapeutics SAGE Stock Holding History

Ballentine Partners’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-4,360
Closed -$310K – 437
2017
Q1 		$310K Hold
4,360
– – 0.02% 171
2016
Q4 		$223K Buy
+4,360
New +$206K 0.02% 168

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Ballentine Partners's SAGE Position: Q2 2017 in Review

Ballentine Partners sold out of Sage Therapeutics (SAGE) in Q2 2017, closing a stake of 4,360 shares — an estimated $310K sold.

Ballentine Partners first reported a position in SAGE in Q4 2016 and held it in 2 quarters. The position peaked at $310K in Q1 2017. 190 funds tracked by Wall St. Rank hold SAGE as of Q2 2017.

  • Ballentine Partners reported no remaining Sage Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Ballentine Partners sold 4,360 Sage Therapeutics shares in Q2 2017, an estimated $310K.
  • Ballentine Partners first reported a position in Sage Therapeutics in Q4 2016 and held it in 2 quarters.
  • Ballentine Partners's Sage Therapeutics position peaked at $310K in Q1 2017.
  • 190 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2017.

Based on Ballentine Partners's 13F filing for Q2 2017, filed 3 Aug 2017.